Soledad Bárez-López1,2, Carmen Grijota-Martínez1,2, Eva Ausó1,3, Mario Fernández-de Frutos1, Ana Montero-Pedrazuela1, Ana Guadaño-Ferraz1,2. 1. Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain. 2. Unit 708, Center for Biomedical Research On Rare Diseases (Ciberer), Instituto de Salud Carlos III, Madrid, Spain. 3. Departamento de Óptica, Farmacología y Anatomía, Universidad de Alicante, Alicante, Spain.
Abstract
Background: Mutations in the thyroid hormone (TH) transporter monocarboxylate transporter 8 (MCT8) lead to peripheral hyperthyroidism and profound psychomotor alterations in humans. Mice lacking Mct8 present peripheral hyperthyroidism but no gross neurological abnormalities due to brain compensatory mechanisms involving the enzyme deiodinase type 2 (Dio2). Methods: Here we have analyzed the endocrine and neurologic phenotype of mice lacking both Mct8 and Dio2 at three and six months of age. Thyroxine (T4) and 3,5,3' triiodothyronine (T3) levels/content were measured by specific radioimmunoassays; motor skill performance was evaluated by the footprint, rotarod, four limb hanging wire, and balance beam tests; and brain histological analysis was performed by immunostaining for neurofilament and parvalbumin. Results: We have found that this mouse model presents peripheral hyperthyroidism and brain hypothyroidism. Interestingly, the severity of the brain hypothyroidism seems permanent and varies across regions, with the striatum being a particularly affected area. We have also found brain alterations at the histological level compatible with TH deficiency and impaired motor skills. Conclusions: These findings indicate the potential of Mct8/Dio2-deficient mice to represent a model for human MCT8 deficiency, to understand the mechanisms underlying its pathophysiology, and ultimately design therapeutic interventions for human patients.
Background: Mutations in the thyroid hormone (TH) transporter monocarboxylate transporter 8 (MCT8) lead to peripheral hyperthyroidism and profound psychomotor alterations in humans. Mice lacking Mct8 present peripheral hyperthyroidism but no gross neurological abnormalities due to brain compensatory mechanisms involving the enzyme deiodinase type 2 (Dio2). Methods: Here we have analyzed the endocrine and neurologic phenotype of mice lacking both Mct8 and Dio2 at three and six months of age. Thyroxine (T4) and 3,5,3' triiodothyronine (T3) levels/content were measured by specific radioimmunoassays; motor skill performance was evaluated by the footprint, rotarod, four limb hanging wire, and balance beam tests; and brain histological analysis was performed by immunostaining for neurofilament and parvalbumin. Results: We have found that this mouse model presents peripheral hyperthyroidism and brain hypothyroidism. Interestingly, the severity of the brain hypothyroidism seems permanent and varies across regions, with the striatum being a particularly affected area. We have also found brain alterations at the histological level compatible with TH deficiency and impaired motor skills. Conclusions: These findings indicate the potential of Mct8/Dio2-deficient mice to represent a model for humanMCT8 deficiency, to understand the mechanisms underlying its pathophysiology, and ultimately design therapeutic interventions for humanpatients.
Entities:
Keywords:
Mct8 deficiency; deiodinase type 2; histological brain impairments; motor skills impairments; mouse model
Authors: Mary E Gilbert; Katherine L O'Shaughnessy; Susan E Thomas; Cal Riutta; Carmen R Wood; Alicia Smith; Wendy O Oshiro; Richard L Ford; Michelle Gatien Hotchkiss; Iman Hassan; Jermaine L Ford Journal: Toxicol Sci Date: 2021-08-30 Impact factor: 4.109
Authors: Xiao-Hui Liao; Pablo Avalos; Oksana Shelest; Raz Ofan; Michael Shilo; Catherine Bresee; Shibi Likhite; Jean-Philippe Vit; Heike Heuer; Brian Kaspar; Kathrin Meyer; Alexandra M Dumitrescu; Samuel Refetoff; Clive N Svendsen; Gad D Vatine Journal: Thyroid Date: 2022-05-20 Impact factor: 6.506
Authors: Carmen Grijota-Martínez; Soledad Bárez-López; Eva Ausó; Samuel Refetoff; William H Frey; Ana Guadaño-Ferraz Journal: PLoS One Date: 2020-07-20 Impact factor: 3.240
Authors: Soledad Bárez-López; Carmen Grijota-Martínez; Xiao-Hui Liao; Samuel Refetoff; Ana Guadaño-Ferraz Journal: PLoS One Date: 2019-12-06 Impact factor: 3.240
Authors: Ferdy S van Geest; Nilhan Gunhanlar; Stefan Groeneweg; W Edward Visser Journal: Front Endocrinol (Lausanne) Date: 2021-09-01 Impact factor: 5.555
Authors: Carmen Grijota-Martínez; Soledad Bárez-López; David Gómez-Andrés; Ana Guadaño-Ferraz Journal: Front Neurosci Date: 2020-04-28 Impact factor: 4.677
Authors: Carmen Escalona-Garrido; Patricia Vázquez; Paula Mera; Sebastián Zagmutt; Ester García-Casarrubios; Ana Montero-Pedrazuela; Fernanda Rey-Stolle; Ana Guadaño-Ferraz; Francisco J Rupérez; Dolors Serra; Laura Herrero; Maria Jesus Obregon; Ángela M Valverde Journal: Mol Metab Date: 2020-10-10 Impact factor: 7.422